study suggests that FK506 may be useful in patients with intractable nephrotic syndrome such as MN. Background. There have been no reports on the effect of FK5 06, a new immunosuppressive agent, on Key words: cationized BSA; exogenous antigen; experiexperimental membranous glomerulonephritis (MN ) mental membranous glomerulonephritis; FK506; induced by an exogenous antigen. Therefore we investiproteinuria gated the effects of FK506 on MN induced by cationized bovine serum albumin (C-BSA) in rats. Methods. Two weeks after the rats were immunized with 1 mg of C-BSA and Freund's complete adjuvant, Introduction they received intravenous injections of 3 mg/kg of C-BSA 3 times weekly for 4 weeks. Rats were divided FK506 is a new immunosuppressive agent with a into four groups: group A (n=5) received intramuscu-molecular action similar to cyclosporin A (CsA). These lar injections of 3 mg/kg of FK506 daily for 5 days immunosuppressive agents inhibit the activation of beginning 2 days before the first immunization; group several transcription factors such as nuclear factor B (n=4) received 1 mg/kg of FK506 daily for 2 weeks (NF ) of activated T cells (NF-AT ) and NF-k B, which beginning 2 weeks after the first immunization; and are critical for T-cell activation [1]. FK506 is a more group C (n=4) received 1 mg/kg of FK506 daily for potent inhibitor of antigen-driven T-cell activation, 2 weeks beginning 4 weeks after the first immunization. cytokine production, and lymphocyte proliferation in Group D (n=5) received no FK506 and served as the vitro than CsA [2]. The systemic level of FK506 control group. Rats were sacrificed 8 weeks after the required to induce and maintain immune suppression first immunization.
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is approximately 100-fold below the corresponding Results. Administration of FK506 in the preimmuniza-blood levels of CsA [3] . FK506 was recently approved tion stage almost completely suppressed the develop-in the USA for the treatment and prevention of graftment of MN in group A. Histological findings in versus-host rejection after solid-organ and bonegroups B and C were similar to those in group D, the marrow transplantation [4] . However, data on the use control group. However, urinary protein excretion was of FK506 to treat human glomerulonephritis is limited significantly lower in group B (24±46 mg/day) and C [5, 6 ] . Studies have shown that FK506 is effective in (220±44 mg/day) than in group D (330±61 mg/day). animal models of spontaneous lupus nephritis [7, 8] Expression of intracellular adhesion molecule-1 in and nephritis induced by endogenous antigens such glomeruli and the number of leukocyte functioning-as Masugi nephritis [9, 10] and Heymann nephritis associated molecules-1 were significantly decreased in [10, 11] . However, there have been no reports on the groups A, B, and C compared with the control group. effect of FK506 on experimental membranous glomAdministration of FK506 was not associated with any erulonephritis (MN ) induced by an exogenous antigen. significant side-effects or histological abnormalities. We investigated the effects of FK506 on MN induced The whole-blood trough levels of FK506 in groups B by cationized bovine serum albumin (C-BSA) in rats. and C were 9.1 ng/ml and 9.2 ng/ml respectively.
Conclusions. The efficacy of FK506 was significantly

Subjects and methods
increased when the drug was administered in the early phase of immunization in this model. The present
Preparation of antigen
To prepare C-BSA, crystallized unmodified BSA (Sigma
Immunosuppressive agent
and polyclonal rabbit anti-mouse tumour necrosis factor-a (TNF-a) [17] purchased from Genzyme, Cambridge, MA, FK506 was kindly provided by Fujisawa Pharmaceutical Co.
USA. For the indirect immunofluorescence method, the (Osaka, Japan) and was dissolved in saline for injections. secondary antibodies were FITC-conjugated anti-mouse IgG and goat anti-rabbit IgG (OrganonTeknika Corp.). These
Experimental design
secondary antibodies were absorbed with rat serum before use to avoid non-specific cross-reaction between rat IgG and Six-week-old female Wistar rats (Doken Co., Shimodate, the antibodies. For the ABC method, the secondary antibodIbaraki, Japan) weighing 150 g were immunized with 1 mg ies were peroxidase-conjugated horse anti-mouse IgG and of C-BSA and Freund's complete adjuvant. Two weeks later, goat anti-rabbit IgG (Funakoshi Inc., Tokyo, Japan). The rats were injected intravenously with 3 mg/kg of C-BSA 3 ABC method was performed according to the manufacturer's times weekly every other day for 4 weeks. Rats were divided instructions except for absorption of antibodies with rat into four groups: group A (n=5) received intramuscular serum. injections of 3 mg/kg of FK506 daily for 5 days beginning 2 days before the first immunization; group B (n=4) received
Evaluation of immunofluorescence and
daily injections of 1 mg/kg of FK506 for 2 weeks beginning immunohistochemistry 2 weeks after the first immunization; group C (n=4) received daily injections of 1 mg/kg of FK506 for 2 weeks beginning
The sections were examined without prior knowledge by two 4 weeks after the first immunization, and group D (n=5) of us (MK and KM ). The intensity of ICAM-1 was graded served as the disease control group and received no FK506.
as none (−), trace (±), mild (1+), moderate (2+), or severe All rats were sacrificed 8 weeks after the first immunization.
(3+), and semiquantitatively scored as follows: (−) 0, (±) 0.5 point, (1+) 1 point, (2+) 2 points, and (3+) 3 points.
Measurements of urinary protein and serum parameters
Cells positive for LFA-1 were counted in 10 randomly selected glomeruli. The data are expressed as the number of Urine samples were collected weekly. Blood samples were positive cells per glomerulus. collected every 2 weeks. At sacrifice, rats were anaesthetized and blood was obtained via cardiac puncture. The animals
Measurement of serum levels of anti-C-BSA antibody
were then immediately killed and the kidneys were removed.
The daily urinary protein excretion was measured using The serum level of antigen-specific IgG was measured by the Kingsburg-Clark method. Serum levels of creatinine, ELISA. Briefly, flat-bottomed microtitre plates were coated total cholesterol, and albumin were measured with an overnight with 0.5 mg/well of C-BSA in 0.02 M sodium autoanalyser.
carbonate buffer, pH 9.8. After the wells were washed five times with phosphate-buffered saline (PBS ) containing 0.05%
Histological examination
Tween 20 (PBS/T ), blocking was performed using 1% Block Ace solution (Yamanouchi Pharmaceutical Co., Tokyo, Kidney specimens were routinely processed for light, Japan), and the plates were incubated at room temperature immunofluorescence, and electron microscopy as described for 1 h. The wells were then washed as before and serum previously [13] . For light microscopy, sections fixed in 10% samples diluted in 1% Block Ace solution were added in buffered formalin were stained with haematoxylin-eosin duplicate or triplicate, plates were then incubated at 37°C (H&E), periodic acid-Schiff (PAS), periodic acid-Schiff for 1 h. After wells were washed, 50 m1 of peroxidasemethenamine silver (PAM ), and Masson's trichrome. Frozen conjugated goat anti-rat IgG (×1000) in 1% Block Ace sections for immunofluorescence microscopy were stained solution was added to the wells. After plates were incubated with FITC-labelled rabbit anti-rat IgG and C3 (Organon for an additional hour and washed, 100 m1 of an Teknika Corp., West Chester, PA, USA). Tissues for electron o-phenylenediamine substrate solution was added. The reacmicroscopy were fixed immediately in 3% glutaraldehyde. tion was stopped by the addition of 50 ml of stopping buffer Ultra-thin sections were stained with uranyl acetate and (2 mM NaN 3 ) and the absorbance was determined at 450 nm. lead citrate.
Data were expressed as OD 450 units.
Polyethyleneimine (PEI) staining Trough levels of FK506 in whole blood
To identify anionic sites in the glomerular basement mem-We measured the trough levels of FK506 in whole blood brane (GBM ), specimens were subjected to the PEI (MW: from groups B and C using a two-step enzyme immunoassay 1800) immersion method of Schurer et al. [14] . The number (EIA) [18] . Briefly, blood samples were obtained in groups of PEI particles per 1 mm of GBM was determined at 10 B and C 24 h after the last FK506 injection. Heparinized GBM sites. The average of the 10 determinations is the PEI whole blood (0.5 ml ) was extracted by dichloromethane. score. A 2000-line/mm diffraction grating (Okenshoji, Tokyo, Samples were processed by two-step EIA in a flat-bottom Japan) was used for calibration. microtitre plate. The detection limit was 0.5 ng/ml.
Statistical analysis Immunohistochemistry
Indirect immunofluorescence or avidin-biotin complex Data are expressed as the mean±standard deviation. Data were analysed using the unpaired t test or the Mann-Whitney (ABC ) method was performed on frozen sections. The following primary antibodies were used: monoclonal mouse U test. A level of P<0.05 was considered statistically significant. anti-rat intracellular adhesion molecule-1 (ICAM-1) [15] 
Urine protein excretion
Urinary protein excretion was less than 10 mg/day in all rats in the preimmunization phase and at 1 and 2 Histological findings weeks after immunization ( Figure 1) , and showed no There were no significant differences in light microsignificant change throughout the experimental period scopic findings among groups. Immunofluorescence in group A. Urinary protein excretion in group B was microscopy showed marked rat IgG and C3 staining similar to that in group A and was significantly lower in the peripheral capillary walls and to some extent in than in group D by 5 weeks. Urinary protein excretion the mesangial area in groups B, C, and D in inverse gradually increased in group D. At 8 weeks, urinary order of intensity ( Table 2) . Weak staining was protein excretion was significantly lower in group C observed in group A. than in group D (Figure 1, Table 1 ).
Transmission electron microscopy showed no electron-dense deposits ( EDDs) in the glomerular baseSerum parameters ment membrane or the mesangial area in group A ( Figure 2 ). Patchy subepithelial EDDs were observed There was no significant difference in the serum creatinine level at 8 weeks among groups ( group showed intraglomerular cells and subepithelial cells that were positive for TNF-a.
distribution of subepithelial EDDs was observed in Serum anti C-BSA antibody titre groups C and D (MN stage I to II ). The anti C-BSA titres were significantly lower in group A than group D, although titres in group A were not PEI staining of the GBM completely negative between 2 and 8 weeks after immunization ( Figure 5 ). The titres in groups C and The PEI score was similar in groups C and D, which was significantly lower than in groups A and B D increased rapidly by 2 weeks after immunization and remained elevated throughout the experiment. The ( Table 2 ), indicating that the anionic sites of the GBM were relatively well preserved in groups A and B titres in group B were similar to those in groups C and D, except for a significant decline in group B at 6 weeks. (Figure 3) . nephropathy and proteinuria level in each group was the same as in preliminary experiments (data not shown) which preceded this study. Urinary protein Trough levels of FK506 excretion tends to be negatively correlated with the The whole-blood trough levels of FK506 24 h after PEI staining in all groups, indicating that FK506 the last injection of FK506 was 9.1±1.1 ng/ml and protected the anionic charge of glomerular capillary 9.2±0.8 ng/ml in groups B and C respectively. walls, resulting in decreased urinary protein excretion. There was no significant difference in the anti C-BSA antibody titre among groups B, C, and D, except at 6 Discussion weeks. These findings suggest that the dose and duration of FK506 treatment in these phases did not result The induction of MN by C-BSA was almost completely in profound suppression of the B-cell system. suppressed when FK506 was administered during the Except in group A, no clear modification of serum preimmunization stage in group A. No significant C-BSA antibody titres was observed in the other three glomerular lesions or specific antibody responses were groups and the IgG and C3 scores in groups B and C were not statistically different from those in group D. observed, presumably because FK506 prevented the These results suggest that FK506 does not significantly blood trough levels indicated. The renal vasoconstriction induced by FK506 results from the increased suppress antibody formation in the stages of MN of groups B and C and that the proteinuria decreasing production of the vasoconstrictors endothelin and thromboxane A2 [28] . We cannot exclude the possibileffect of FK506 is due to other factors rather than the B-cell system suppression. A number of factors are ity that the decrease of proteinuria in groups B and C could be partially due to a decrease in the glomerular involved in the pathogenesis of experimental MN, including complement, active oxygens, and cytokines filtration rate because we did not measure this parameter. [10, 20] . Adhesion molecules are critical factors in the immune response [21] . Kawasaki et al. [22] reported We observed that FK506 had a beneficial effect on proteinuria even when MN was established. In the that the injection of antibodies directed against ICAM-1 and LFA-1 prevented the development of rat present study, however, we only investigated its effect in the early phase of membranous nephropathy. experimental crescentic glomerulonephritis. In the present studies, ICAM-1 was not expressed in group A Further analysis of the effect of FK506 in the middle and later phases of glomerulonephritis is needed to rats and ICAM-1 expression in the capillary and mesangial areas was weaker in groups B and C than confirm whether FK506 is useful in these phases or not.
In conclusion, the efficacy of FK506 was significantly in group D. The number of intraglomerular cells positive for LFA-1 was significantly higher in group D increased when the drug was administered in the early phase of immunization in this model. The present than in the other groups. We suggest that FK506 may have suppressed the expression of ICAM-1 and LFA-1 study suggests that FK506 may be useful in patients with intractable nephrotic syndrome such as MN. in this model, although a relationship between proteinuria and ICAM-1 and LFA-1 between groups A,
